Phase 1 clinical study has investigated AMG 232, a selective MDM2 inhibitor that restores p53 tumour suppression by blocking the MDM2–p53 interaction with picomolar affinity [57] appears to be safe and could provide a strategy to target CDKN2A deleted MPMs, which harbour wild-type p53. The gene discussed is MDM2; the disease is neoplasm.